

IN THE SEQUENCE LISTING

Please insert the attached paper copy of the Sequence Listing, containing pages 1 and 2, at the end of the specification.

REMARKS

Justification for the amendments is as follows. The amendments to the specification at page 2, page 4, page 21, page 44, and page 57 were made to correct the included citations. The above amendment to the Sequence Listing provides a Sequence Listing in compliance with the requirements of 37 C.F.R. 1.821 through 1.825, as requested by the Notice to Comply dated 20 December 2000 in the above-referenced case. The sequences contained in the Sequence Listing are disclosed in the application as originally filed. Namely, SEQ ID NO:1 appears in the specification at page 46, line 6; SEQ ID NO:2 appears in the specification at page 46, line 7; SEQ ID NO:3 appears in the specification at page 46, line 21; SEQ ID NO:4 appears in the specification at page 46, line 22; SEQ ID NO:5 appears in the specification at page 47, line 5; SEQ ID NO:6 appears in the specification at page 47, line 6; and SEQ ID NO:7 appears in the specification at page 47, line 18, and at page 47, line 21. The remaining amendments to the specification incorporate sequence identifiers into the specification as appropriate. No new matter is added by any of these amendments.

If there are any questions regarding the present communication, please call Applicants' Attorney at 650-866-7254.

Respectfully submitted,

Date:

6 March 01



Leanne C. Price, Esq.
Reg. No. 42,090

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco, CA 94080
Main: 650-866-7200
Direct: 650-866-7254
Facsimile: 650-866-7204